Martin Heidecker, PhD, MBA, joined the AMR Action Fund in August 2021, bringing with him extensive international experience in venture capital, drug development, and pharmaceutical marketing. Most recently, he was Managing Director USA of Boehringer Ingelheim Venture Fund in Boston, where he built a portfolio spanning multiple therapeutic areas, including oncology, central nervous system disorders, and anti-infectives, and led numerous companies to successful exits through M&As, IPOs, and product launches. Martin’s investing career began in Germany with Bayern Kapital, where he focused on seed investments in German biotechnology companies.
Over the years, he has served on the board of directors at numerous biotech companies, including Tilos Therapeutics Inc. (acquired by Merck) and Armagen Technologies (acquired by JCR Pharmaceuticals). His deep understanding of the global biopharmaceutical industry is informed by his work at Solvay Pharmaceuticals and Boehringer Ingelheim, where he held a position in business development and marketing and helped launch several successful CNS drugs. He holds a PhD in biology from University of Würzburg and an MBA from FernUniversität Hagen.